General description
A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC50 = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.
A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC50 = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.
Please note that the molecular weight for this compound is batch-specific due to variable water content.
Biochem/physiol Actions
Primary Target
Ca2+-activated K+ channels
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Leurangue, V. et al. 2008. Naunyn Schmiedebergs Arch. Pharmacol.377, 101.
Morimura, K. et al. 2006. J. Pharmacol. Sci.100, 237.
Strobaek, D. et al. 2004. Biochim. Biophys. Acta.1665, 1.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 41116133
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 5085090001
